| Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice G Boysen, A Jamshidi-Parsian, MA Davis, ER Siegel, CM Simecka, ... International journal of radiation biology 95 (4), 436-442, 2019 | 95 | 2019 |
| 4-Methyl-1,2,3-Triazoles as N-Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity H Cui, AS Carlson, MA Schleiff, A Divakaran, JA Johnson, CR Buchholz, ... Journal of medicinal chemistry 64 (14), 10497-10511, 2021 | 25 | 2021 |
| Meloxicam methyl group determines enzyme specificity for thiazole bioactivation compared to sudoxicam DA Barnette, MA Schleiff, A Datta, N Flynn, SJ Swamidass, GP Miller Toxicology letters 338, 10-20, 2021 | 22 | 2021 |
| Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches DA Barnette, MA Davis, NL Dang, AS Pidugu, T Hughes, SJ Swamidass, ... Biochemical pharmacology 156, 10-21, 2018 | 22 | 2018 |
| Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam DA Barnette, MA Schleiff, LR Osborn, N Flynn, M Matlock, SJ Swamidass, ... Toxicology 440, 152478, 2020 | 20 | 2020 |
| CYP2C19 and 3A4 dominate metabolic clearance and bioactivation of terbinafine based on computational and experimental approaches MA Davis, DA Barnette, NR Flynn, AS Pidugu, SJ Swamidass, G Boysen, ... Chemical research in toxicology 32 (6), 1151-1164, 2019 | 20 | 2019 |
| Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation DA Barnette, MA Davis, N Flynn, AS Pidugu, SJ Swamidass, GP Miller Biochemical pharmacology 170, 113661, 2019 | 15 | 2019 |
| Significance of multiple bioactivation pathways for meclofenamate as revealed through modeling and reaction kinetics MA Schleiff, NR Flynn, S Payakachat, BM Schleiff, AO Pinson, ... Drug Metabolism and Disposition 49 (2), 133-141, 2021 | 11 | 2021 |
| Advances in the study of drug metabolism–symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX) LE Russell, MA Schleiff, E Gonzalez, AG Bart, F Broccatelli, JH Hartman, ... Drug metabolism reviews 52 (3), 395-407, 2020 | 7 | 2020 |
| CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs MA Schleiff, S Crosby, M Blue, BM Schleiff, G Boysen, GP Miller Biochemical pharmacology 194, 114824, 2021 | 6 | 2021 |
| Impacts of diphenylamine NSAID halogenation on bioactivation risks MA Schleiff, S Payakachat, BM Schleiff, SJ Swamidass, G Boysen, ... Toxicology 458, 152832, 2021 | 6 | 2021 |
| Recent developments in predicting CYP-independent metabolism NV Dhuria, B Haro, A Kapadia, KA Lobo, B Matusow, MA Schleiff, ... Drug Metabolism Reviews, 2021 | 6 | 2021 |
| Significance of competing metabolic pathways for 5F-APINACA based on quantitative kinetics AO Pinson, DL Pouncey, MA Schleiff, WE Fantegrossi, PL Prather, ... Molecules 25 (20), 4820, 2020 | 6 | 2020 |
| Bioactivation of isoxazole-containing bromodomain and extra-terminal domain (BET) inhibitors NR Flynn, MD Ward, MA Schleiff, CMC Laurin, R Farmer, SJ Conway, ... Metabolites 11 (6), 390, 2021 | 3 | 2021 |
| Recent advances in computational metabolite structure predictions and altered metabolic pathways assessment to inform drug development processes MA Schleiff, D Dhaware, JK Sodhi Drug Metabolism Reviews 53 (2), 173-187, 2021 | 3 | 2021 |
| The role of cytochrome P450 3A4-mediated metabolism in sorafenib and lapatinib hepatotoxicity MR McGill, Y Kaufmann, FV LoBianco, MA Schleiff, N Aykin-Burns, ... Livers 3 (2), 310-321, 2023 | 2 | 2023 |
| International Society for the Study of Xenobiotics (ISSX) New Investigator Group Committee 2019–2020 concluding remarks MA Schleiff, JK Sodhi Drug Metabolism Reviews 53 (2), 279-284, 2021 | 1 | 2021 |
| Similar 5F-APINACA Metabolism between CD-1 Mouse and Human Liver Microsomes Involves Different P450 Cytochromes SV Crosby, IY Ahmed, LR Osborn, Z Wang, MA Schleiff, WE Fantegrossi, ... Metabolites 12 (8), 773, 2022 | | 2022 |
| Structural Variations among Marketed Diphenylamine NSAIDs Determine Preference and Efficiency for Four Possible Bioactivation Pathways M Schleiff, S Payakachat, G Miller, G Boysen, J Swamidass The FASEB Journal 35, 2021 | | 2021 |
| Novel Bioactivation of Isoxazole‐containing Bromodomain and Extra Terminal Domain (BET) Inhibitors G Miller, M Schleiff, N Flynn, M Ward, C Laurin, S Conway, S Swamidass The FASEB Journal 35, 2021 | | 2021 |
Gunnar BoysenUniversity of Arkansas for Medical Sciences在 uams.edu 的电子邮件经过验证
